ArticleBiomaterials research2025
Optimizing the Surface Functionalization of Peptide-MXene Nanoplatforms to Amplify Tumor-Targeting Efficiency and Photothermal Therapy.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Energy storage and conversion extensively use MXenes, a class of 2-dimensional transition metals. Research is currently exploring MXenes in areas such as biomedical imaging, positioning them as a substantial contender in biomedical applications. Even though these biocompatible MXenes have many uses, it is challenging to make nanoparticles that are all the same size. This has made it harder to use them in the biomedical field. Herein, we meticulously crafted nano-sized MXene particles, achieving exceptional uniformity and amplified photothermal conversion efficiency compared to those of their bulkier micro-sized counterparts. To make these nanoparticles better at finding tumors, we added ARGD peptides to their surfaces. These are biomolecules that are known to bind to integrin α
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.